Salvia BioElectronics has successfully closed a Series B funding round of no less than $60 million to bring its groundbreaking migraine therapy to market. The round was led by Innovation Industries, with participation from Invest-NL, the EIC Fund, My Global Family Office (MGFO), and existing investors including Inkef, Panakès Partners, SHS Capital, Dolby Family Ventures, Brabant Development Agency (BOM), and Thuja Capital.
This substantial investment will enable Salvia to complete the clinical development phase and prepare for the commercial launch of MySalvia Therapy in the United States, Europe, and Australia.
A personal mission to relieve chronic migraine
Salvia BioElectronics is developing MySalvia Therapy – an innovative, personalized treatment for people suffering from chronic migraine. Based on neuromodulation technology and applied in a minimally invasive way, the therapy is designed to reduce the frequency and intensity of migraine attacks. Instead of relying solely on medication, Salvia offers a solution that directly influences the nervous system using bioelectrical signals.
Hubert Martens, founder and CEO of Salvia BioElectronics, explains:
"With the support of this strong syndicate of investors, we can make MySalvia Therapy available to patients who are in urgent need of new treatment options. Chronic migraine is not ‘just a headache.’ It is a debilitating neurological disorder that pushes people out of their social life, work, and daily functioning. Our mission is to restore their freedom."
Caaj Greebe, Partner at Innovation Industries, adds:
"Salvia BioElectronics is redefining the migraine treatment landscape with a bold, patient-centered approach that combines advanced neuromodulation with an elegant, minimally invasive design."
Toward market launch
Thanks to this funding, Salvia is taking major steps toward regulatory approval and commercialization of its therapy, aiming to help millions of people worldwide who suffer from chronic migraine. A major milestone on the path toward relief — and freedom — for countless patients.
